The Impact of Incretins on Fat-free Mass, Muscle Strength and Functional Capacity

What this study involves

The registry says this study is recruiting. Individual locations may have different availability.

Study type

Observational

Phase

Not applicable / not listed

Age range

18 years - Not specified

Sex eligible

All sexes

Healthy volunteers

Not accepted

Participants

200 Estimated

These are starting points, not an eligibility decision. The research team must review the full requirements.

About the research

The goal of this observational study is to learn how treatment with incretins, such as semaglutide and tirzepatide, affects muscle mass, muscle strength, and physical function in people with overweight or obesity.

The main questions this study aims to answer are:

• What is the composition of weight loss during incretin treatment?
• What is the composition of recurrent weight gain after stopping incretin treatment?

An additional question this study aims to answer is:

\- How do muscle strength and physical function change during and after incretin treatment?

Two groups of patients will be included: patients who start with incretin therapy for overweight/obesity and patients who stop incretin therapy for overweight/obesity.

Participants who start incretin treatment will have measurements before starting treatment, after six months, and after twelve months or when treatment is stopped. Participants who stop incretin treatment will have measurements before stopping treatment, after six months, and after twelve months or before restarting treatment.

Measurements include:

• Height, length, waist circumference
• Body composition measured with InBody, with a Dual-Energy X-ray Absorptiometry in a subgroup of the participants
• Muscle strength tests
• Physical function tests
• Blood samples to asses metabolic health
• Physical activity measured with an activity monitor (ActivPAL)
• Questionnaires about health, incretin treatment, physical activity, and diet

No treatment or medication will be given as part of the study. Participants will receive incretin treatment as part of their usual care.

Who may be able to participate?

The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.

Inclusion Criteria:

• Screened and planned to start with incretin treatment or currently using incretin and planned to discontinue treatment.
• Aged 18 years or older

Exclusion Criteria:

• Inability to comprehend scheduled procedures (e.g., language barriers)
• Unable to perform the physical tests due to physical disabilities
• Patients who underwent MBS or including endoscopic interventions and gastric balloon placement.
• Prior use of incretins, or other obesity medication.

Study population

People with overweight or obesity

Treatment, groups and participation

The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.

Assignment

Not reported

Masking

Not reported

What researchers are measuring

Outcome measures describe what is being studied. They are not proof that a treatment works.

Primary measures

Secondary measures

Other measures

Research locations (2)

The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.

2 locations

Study team and timeline

Lead sponsor

Radboud University Medical Center

Study start

Aug 28, 2026 Actual

Primary completion

Feb 1, 2027 Estimated

Study completion

Mar 1, 2027 Estimated

First posted

Nov 10, 2026 Actual

Last updated

Nov 10, 2026 Actual

Official study contacts